<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624505</url>
  </required_header>
  <id_info>
    <org_study_id>U-SS-M-AS312</org_study_id>
    <nct_id>NCT02624505</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma</brief_title>
  <official_title>To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cipla Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cipla Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test
      product to the reference product, using bronchoprovocation (methacholine challenge testing)
      in adult patients with stable mild asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to demonstrate the pharmacodynamic bioequivalence of the test product to the
      reference product in terms of FEV1 measured at different time-points, using
      bronchoprovocation (methacholine challenge testing) in adult patients with stable mild
      asthma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Provocative Concentration of Methacholine Causing 20 % Fall (PC20) in FEV1(Forced Expiratory Volume in 1 second)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo Product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mcg Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug : 90 mcg Reference Product One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mcg Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: 180 mcg Reference Product One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mcg Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: 90 mcg Test Product One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg Reference Product</intervention_name>
    <description>Drug: 90 mcg Reference Product</description>
    <arm_group_label>90 mcg Reference Product</arm_group_label>
    <other_name>Albuterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>180 mcg Reference Product</intervention_name>
    <description>Drug: 180 mcg of Reference Product</description>
    <arm_group_label>180 mcg Reference Product</arm_group_label>
    <other_name>Albuetrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90 mcg Test Product</intervention_name>
    <description>Drug: 90 mcg of Test Product</description>
    <arm_group_label>90 mcg Test Product</arm_group_label>
    <other_name>Albuterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Product</description>
    <arm_group_label>Placebo Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and non-pregnant female subjects (18-65 years of age)

          -  Forced Expiratory Volume in 1 second (FEV1) ≥ 80% of predicted. Airway responsiveness
             to methacholine demonstrated by a pre-albuterol dose (baseline) PC20 ≤ 8 mg/ml.

          -  Stable mild asthmatics based on National Asthma Education and Prevention Program
             (NAEPP) guidelines.

          -  Nonsmokers for at least 6 months prior to the study and a maximum smoking history of
             five pack-years (the equivalent of one pack per day for five years).

          -  Written informed consent.

        Exclusion Criteria:

          -  Conditions which could alter airway reactivity to methacholine (e.g., pneumonia, upper
             respiratory tract infection, viral bronchitis and/or sinobronchitis) within six weeks
             prior to the screening visit.

          -  History of seasonal asthma exacerbations, in which case the patient should be studied
             outside of the relevant allergen season.

          -  History of a clinically significant disease or abnormality including congestive heart
             failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial
             infarction, or cardiac dysrhythmia.

          -  History of cystic fibrosis, bronchiectasis or other respiratory diseases other than
             Asthma

          -  Historical or current evidence of significant hematologic, hepatic, neurologic,
             psychiatric, renal, or other diseases

          -  Known intolerance or hypersensitivity or hypersensitivity to any component of the
             albuterol metered dose inhaler (MDI).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhiraj Abhyankar</last_name>
    <role>Study Chair</role>
    <affiliation>Cipla Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gulam Kadiri</last_name>
    <phone>00912225756457</phone>
    <email>gulam.kadiri@cipla.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeevan Yewale</last_name>
    <phone>00912225756569</phone>
    <email>jeevan.yewale@cipla.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Colorado Allergy and Asthma Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Pearlman, MD</last_name>
      <phone>720-858-7510</phone>
      <email>ds.pearlman@coloradoallergy.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

